{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:56:33Z","timestamp":1745470593224,"version":"3.40.4"},"reference-count":10,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T00:00:00Z","timestamp":1202256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T00:00:00Z","timestamp":1202256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron Clin Pract"],"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Secondary hyperparathyroidism remains a serious problem in hemodialysis patients. The therapy of renal osteodystrophy is mainly based on lowering phosphate levels and administering vitamin D&lt;sub&gt;3&lt;\/sub&gt; metabolites and calcimimetic agents. &lt;i&gt;Methods:&lt;\/i&gt; An observational, prospective, multicenter study was made to evaluate the efficacy of alfacalcidol in 185 chronic hemodialysis patients with secondary hyperparathyroidism (i-PTH &gt;150 pg\/ml). Patients with a Ca\u00d7P product &gt;70 were excluded. Intermittent therapy with intravenous alfacalcidol was observed for 6 months. &lt;i&gt;Results:&lt;\/i&gt; The mean dose of alfacalcidol per week was 3.63 \u00b1 1.71 \u00b5g. Patients previously treated with vitamin D&lt;sub&gt;3&lt;\/sub&gt; metabolites needed higher doses of alfacalcidol (4.0 \u00b1 1.7 vs. 3.2 \u00b1 1.6; p = 0.01). Only 50.8% of the patients had received vitamin D&lt;sub&gt;3&lt;\/sub&gt; metabolites prior to the start of the study and at baseline they had higher i-PTH levels (600.3 \u00b1 360.5 vs. 489.9 \u00b1 292.6, p = 0.02). i-PTH levels decreased from 546 \u00b1 332.6 to 332.4 \u00b1 274.5 pg\/ml (p &lt; 0.001). 60.5% of the patients had i-PTH &lt; 300 pg\/ml at the last observation. Serum calcium increased (9.4 \u00b1 0.8 to 9.97 \u00b1 1.0 mg\/l, p &lt; 0.001). &lt;i&gt;Conclusion:&lt;\/i&gt; Alfacalcidol reduced the levels of i-PTH and produced a slight increase in serum calcium and phosphate levels. In mild or moderate hyperparathyroidism the doses needed were lower than in severe hyperparathyroidism.<\/jats:p>","DOI":"10.1159\/000115326","type":"journal-article","created":{"date-parts":[[2008,2,7]],"date-time":"2008-02-07T10:22:50Z","timestamp":1202379770000},"page":"c141-c147","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Intravenous Alfacalcidol in the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis"],"prefix":"10.1159","volume":"108","author":[{"given":"M.T.","family":"Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.V.","family":"Torregrosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Colom\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mendia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pavesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2008,2,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfh1002"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2796.1996.469810000.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2F0272-6386%2895%2990453-0"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053%2Fj.ajkd.2004.08.009"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfl006"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfi213"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2165%2F00003495-200363060-00005"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1523-1755.2004.09006.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038%2Fki.1993.92"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016%2F0272-6386%2895%2990454-9"}],"container-title":["Nephron Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/115326","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/115326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:09:33Z","timestamp":1745460573000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000115326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,6]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000115326","archive":["Portico"],"relation":{},"ISSN":["1660-2110"],"issn-type":[{"type":"electronic","value":"1660-2110"}],"subject":[],"published":{"date-parts":[[2008,2,6]]}}}